203 results about "Thymus Glands" patented technology

Described herein are novel and improved antibodies that bind to thymic stromal lymphopoietin (TSLP) and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP. In certain aspects, described herein are methods of treating asthma by administering anti-TSLP antibodies.

The invention discloses preparation of a whey protein peptide mixture with immune and muscle-building effects, and relates to the technical field of food processing and bioengineering. The neutral protease is adopted and the pH is adjusted, so that the enzymolysis efficiency is effectively improved, and the enzymolysis time is greatly shortened; meanwhile, the whey protein peptide which is uniform in molecular weight distribution, free of peculiar smell and good in thermal stability is successfully prepared by accurately controlling enzymolysis conditions and combining microbial fermentation. The protein peptide can effectively improve thymus indexes and spleen indexes, enhance the proliferation capacity of splenic lymphocytes and the activity of NK cells, play an excellent immune regulation role and have a remarkable muscle building effect. The preparation process has the advantages of high efficiency, low cost, simplicity, convenience and the like, gives consideration to high quality and high functionality of the product, and has great application value.

Described herein is a topical formulation. The topical formulation includes a thymine-thymine compound including Formula (1) and a solvent system. The topical formulation includes about 0.01 wt% to about 10 wt% of the thymine-thymine compound, based on total weight of the formulation. A method of preparing the topical formulation is also provided.

Described herein are antibodies, or antigen binding fragments thereof, that bind thymic stromal lymphopoietin (TSLP) and OX40L in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and TSLP biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-TSLP and anti-OX40L antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP and / or OX40L.

Disclosed is an isolated monoclonal antibody that specifically binds human TSLP, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, an immunoconjugate, a CAR-immune cell, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-TSLP antibody of the disclosure.

The invention discloses a synthesis method of 2 '-fluoro-2'-deoxyguanosine. According to the method, thymine nucleoside phosphorylase and purine nucleoside phosphorylase are used as biocatalysts, and 2 '-fluoro-2'-deoxyuridine and guanine are used as substrates to synthesize the 2 '-fluoro-2'-deoxyguanosine. Compared with a chemical method, the production cost is greatly reduced; meanwhile, the synthesis method can effectively solve the problem that the product is difficult to separate.

The invention discloses plant lactobacillus and application thereof in immunoregulation and intestinal environment improvement, and relates to the technical field of microorganisms. The invention provides a strain of plant lactobacillus LIHUO 05, and the preservation number of the plant lactobacillus LIHUO 05 is CGMCC (China General Microbiological Culture Collection Center) No.36240. The invention also provides a preparation method of the plant lactobacillus LIHUO 05. The plant lactobacillus LISUO 05 can be used for promoting macrophages to secrete TNF (Tumor Necrosis Factor)-alpha and IL-1beta; the thermally inactivated strain LIHUO 05 has a certain immunoregulation effect on the body weight, thymus index and TNF-alpha content in serum of immunocompromised mice. Meanwhile, the phytobacterium plantarum LIHUO 05 can change the colon flora structure in the intestinal tract, improve the relative abundance of beneficial bacteria and adjust the variety and number of colon metabolites in the intestinal tract, and has a certain effect of improving the intestinal tract environment.

The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to thymic stromal lymphopoietin (TSLP). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, methods for treating diseases or disorders mediated by thymic stromal lymphopoietin (TSLP), uses of the antibodies or pharmaceutical compositions thereof for treating diseases or disorders mediated by TSLP, and uses of the antibodies and other therapeutically active compounds for treating diseases or disorders mediated by TSLP.

The application discloses a construction method and application of a thymus organoid, and the method is used in combination with small molecule compounds and small molecule proteins to differentiate pluripotent stem cells into the thymus organoid under a suspension culture condition, and the method can efficiently obtain the thymus organoid which is closer to the natural thymus in structure and function.

The present invention relates to a method for treating aging, and in particular immunosenescence, restoring thymic function and regenerating the thymus in a subject in need thereof, comprising the administration of T cell progenitors comprising CD7+CD34- cells.

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate to severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, the method comprises selecting a subject suffering from AD and having an elevated level relative to a control of at least one biomarker selected from the group consisting of thymus activation regulatory chemokine (TARC), interleukin-5 (IL-5), eosinophilic granulocyte count, and lactic dehydrogenase (LDH).

The application provides a thymus disease risk prediction method and system based on cross-modal feature interaction, which comprises the following steps: respectively preprocessing CT image data, MRI image data and image reports; sequentially performing word segmentation, vector conversion, feature extraction and pooling on the third data, inputting the labeled semantic feature vector into an image generation network to generate a PET-CT image; inputting the first data, the second data and the PET-CT image into the same medical mamba feature extraction network respectively to obtain the first modal feature corresponding to the first data, the second modal feature corresponding to the second data and the third modal feature corresponding to the PET-CT image; performing feature fusion interaction on the first modal feature, the second modal feature and the third modal feature to obtain a fusion feature, and obtaining the thymus disease risk according to the fusion feature. The application can greatly improve the thymus disease prediction accuracy.

The present application belongs to the technical field of animal health care, and particularly relates to a fermented decoction for improving growth and immune function of broilers and a preparation method thereof. The fermented decoction for improving growth and immune function of broilers is prepared from the following raw materials by fermentation according to weight parts: radix codonopsis 8-12 parts, angelica sinensis 3-7 parts, cornus officinalis 8-12 parts, cinnamomum cassia 3-7 parts and portulaca oleracea 3-7 parts. The fermented decoction significantly increases the body weight of broilers, significantly improves the thymus index and spleen index, and increases the IgG and IgM contents in serum, thereby promoting the growth of broilers and improving the immune function of broilers. The preparation method of the fermented decoction is simple, and is suitable for industrialized production and market promotion and application.

Disclosed in the present invention are an antibody capable of binding to human thymic stromal lymphopoietin (hTSLP), a preparation method therefor and an application thereof. The anti-hTSLP antibody of the present invention can specifically bind to a hTSLP receptor, has a good effect of inhibiting the secretion of TARC by PBMC, and can be applied to the treatment of TSLP-related diseases, such as immune-mediated inflammatory diseases.

Provided are compositions, methods, and systems for DNA pyrimidine-base editing. In some embodiments, provided are engineered thymine-modifying polypeptides or engineered cytosine-modifying polypeptides comprising a variant of a uracil-DNA glycosylate (UNG). In some embodiments, provided are such engineered polypeptides and a DNA recognition domain, which are configured to target a nucleic acid for excision. Also provided herein are nucleic acid encoding the polypeptides described herein, additional components useful for editing, such as sgRNA, kits, medicines, composition, and method of use thereof.

The present disclosure provides porcine thymolivers, methods of making thereof, and methods of using thereof. The present disclosure further provides methods of treating a disease (e.g., a liver disease) in a human subject in need thereof comprising transplanting of a porcine thymoliver.

The invention relates to the field of biological medicines, and discloses an application of an anti-thymocyte immune globulin preparation in liver transplantation immune induction, which comprises a use method and a dosage of anti-thymocyte immune globulin as an immune inducer in a liver transplantation recipient. Clinical cases prove that liver transplantation recipients use the anti-thymocyte immune globulin as immunosuppressive induction, so that the liver function and lymphocyte level can be quickly recovered to normal ranges, no obvious influence is caused on renal function, the occurrence rate of acute rejection reaction is reduced, the cytomegalovirus infection rate is not increased, and the anti-thymocyte immune globulin can be applied to liver transplantation recipients. Clinical application of the anti-thymocyte immune globulin in immune induction treatment of liver transplantation recipients is expanded, and the anti-thymocyte immune globulin has a great application prospect.

Described herein are methods of modifying or editing a target nucleic acid such as methods that edit adenine to cytosine, thymine, or guanine. Compositions and systems for modifying or editing a target nucleic acid are also described. Methods, compositions and systems described herein may be used for generating allelic diversity.

The application belongs to the technical field of medicines, and specifically provides application of Phanginin A in preparation of medicines for preventing and / or treating skin diseases. The skin diseases include atopic dermatitis and skin epidermal barrier damage. The application finds that Phanginin A can reduce atopic dermatitis lesion scores, improve atopic dermatitis skin pathological thickening and inflammatory cell infiltration, reduce spleen inflammatory response, inhibit volume increase, promote thymus function recovery, down-regulate expression of atopic dermatitis related inflammatory factors IL-6 and TNF-alpha, and can be used for preventing and / or treating atopic dermatitis. In addition, the application also finds that Phanginin A can promote keratinocyte scratch healing, and can be used for repairing skin epidermal barrier damage.

Described herein are antibodies, or antigen binding fragments thereof, that bind thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13 in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP and IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-TSLP and anti-IL-13 antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP and / or IL-13.

The present invention relates to a product derived from allogeneically cultured postnatal thymus tissue for use in a method of inducing thymopoiesis and thereby promoting donor-specific tolerance to an allogeneic solid organ transplant in a recipient requiring a solid organ transplant, such as a heart, lung, liver, or other solid organ or part of a whole solid organ. The product derived from allogeneically cultured postnatal thymus tissue is prepared by subjecting suitable thymus tissue to a conditioning regimen, said conditioning regimen comprising the aseptic processing of the donor thymus tissue in a thymus organ medium and producing sections of donor thymus tissue partially devoid of T cells. The method of preparing the allogeneically cultured postnatal thymus tissue is further disclosed.

The application discloses an immune function enhancing composition which is mixed by sambucus williamsii alcohols extract and lactobacillus rhamnosus agent. The application can effectively immunize the spleen, improve the spleen index and thymus index, has the function of immune regulation, and can also improve the IgM and IgG content in serum.

This invention discloses a universal detection method for tumor antigen-specific thymus-dependent lymphocytes in a broad population of East Asia, applicable to lung cancer and gastrointestinal cancers. The broad-spectrum T-cell epitope peptide library used in this detection method contains specific antigen T-cell epitope peptides presented by 13 HLA-A molecules, 15 HLA-B molecules, and 14 HLA-C molecules with an allele frequency greater than 1% in the East Asian population. The total gene frequencies of these dominant HLA-A, B, and C molecules account for approximately 95%, 71%, and 93% of the Chinese population, respectively, and are similar in total gene frequencies in Northeast and Southeast Asian populations. Therefore, this detection method is applicable to the vast majority of individuals in this region, providing a universal method for evaluating specific tumor antigen-specific T-cell immune function in patients with lung cancer or gastrointestinal tumors.

Described herein are compositions and combinations comprising an antibody or antigen binding fragment thereof that binds thymic stromal lymphopoietin (TSLP), an antibody or antigen binding fragment thereof that binds Interleukin-4 Receptor Alpha (IL-4Ra), and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

The invention provides skin anti-inflammatory application of cyclic polypeptide, the polypeptide contains SEQ ID NO: 1, and disulfide bonds at the head and the tail of the polypeptide are cyclized. The skin anti-inflammatory agent disclosed by the invention comprises the step of inhibiting the expression of thymic stromal lymphopoietin (TSLP), interleukin-13 (IL-13), interleukin-31 (IL-31) and / or interleukin-33 (IL-33). The invention also relates to an application of the cyclic polypeptide in preparation of medicines or external skin preparations for preventing and / or treating Th2 type immune related diseases. The external skin preparations are selected from face cream, emulsion, gel, toning lotion, essence, masks, eye cream, aerosol cleaning foam, spray, shower gel or facial cleanser.

The present application provides novel anti-TSLP and anti-SCF antibodies, and binding domains thereof, as well as bispecific constructs comprising such antibodies and binding domains. The present application also provides treatment of immune response (e.g., immune response) via interaction (e.g., binding) of TSLP and / or SCF with its receptors (e.g., TSLPR and / or c-Kit, respectively) on immune cells by administering to a patient in need thereof the antibodies (or antigen binding fragments thereof), bispecific constructs or compositions described herein, or compositions. Immune cell migration, activation and / or proliferation) related disorders, such as disorders of the immune system.

The invention belongs to the technical field of experimental animal models, biomedical research and immunology, and discloses a photocoagulation thymus ischemia animal model, a method and application of the photocoagulation thymus ischemia animal model in rapid simulation of thymus degeneration and immune senescence, and the model shows at least one or more characteristics 1-7 days after induction: thymus atrophy, thymus weight or thymus index is significantly reduced; the cortical-medullary structure of thymus is disordered or disappears; the expression distribution of the Keratin 5 / Keratin 8 is abnormal; thymic cell apoptosis is increased, and lipid deposition is enhanced; the proportion of CD4 + CD8 + double positive T cells is reduced, and the proportion of DN2 / DN3 stage T cells is increased; the initial T cell output is reduced; and the immune function is reduced. The pathological mechanism is clear; the modeling period is short, and the immune senescence phenotype can be stably obtained within several days; the injury focus is controllable, and systemic stress or hormone interference is avoided; the model has high repeatability and is suitable for mechanism research and drug screening.

The present disclosure, relates, in general, to methods of treating chronic obstructive pulmonary disease (COPD) using an antibody specific for thymic stromal lymphopoietin (TSLP).